Sei Investments Co. lessened its holdings in shares of AstraZeneca plc (NYSE:AZN) by 8.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,426,107 shares of the company’s stock after selling 136,346 shares during the quarter. Sei Investments Co.’s holdings in AstraZeneca were worth $71,059,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in AZN. Fisher Asset Management LLC grew its stake in AstraZeneca by 2.2% during the 3rd quarter. Fisher Asset Management LLC now owns 16,261,961 shares of the company’s stock valued at $724,796,000 after acquiring an additional 357,670 shares in the last quarter. Galibier Capital Management Ltd. grew its stake in AstraZeneca by 525.9% during the 4th quarter. Galibier Capital Management Ltd. now owns 357,770 shares of the company’s stock valued at $17,838,000 after acquiring an additional 300,611 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in AstraZeneca by 7.9% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 2,987,152 shares of the company’s stock valued at $133,137,000 after acquiring an additional 217,690 shares in the last quarter. CWM LLC grew its stake in AstraZeneca by 8,495.7% during the 3rd quarter. CWM LLC now owns 215,839 shares of the company’s stock valued at $9,620,000 after acquiring an additional 213,328 shares in the last quarter. Finally, Trillium Asset Management LLC purchased a new position in AstraZeneca during the 3rd quarter valued at about $7,183,000. 17.44% of the stock is currently owned by institutional investors.

Several equities analysts have weighed in on AZN shares. Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research note on Thursday, October 24th. Cowen reissued an “outperform” rating and issued a $55.00 price target (up previously from $48.00) on shares of AstraZeneca in a research note on Monday, December 2nd. Leerink Swann began coverage on AstraZeneca in a research note on Friday, November 22nd. They issued an “outperform” rating and a $57.00 price target for the company. Svb Leerink began coverage on AstraZeneca in a research note on Friday, November 22nd. They issued an “outperform” rating for the company. Finally, ValuEngine raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $50.35.

Shares of NYSE AZN traded down $1.48 during trading hours on Friday, hitting $47.85. The stock had a trading volume of 6,665,012 shares, compared to its average volume of 2,633,813. The company has a market capitalization of $130.95 billion, a P/E ratio of 58.35, a P/E/G ratio of 1.49 and a beta of 0.48. The firm’s 50-day moving average price is $49.89 and its two-hundred day moving average price is $46.85. AstraZeneca plc has a 52 week low of $36.83 and a 52 week high of $51.55. The company has a debt-to-equity ratio of 1.29, a quick ratio of 0.70 and a current ratio of 0.92.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: What is the Euro STOXX 50 Index?

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.